Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Aspartate receptors" patented technology

The aspartate receptor, Tar, is a member of a family of transmembrane receptors that mediate chemotactic response in certain enteric bacteria, such as Salmonella typhimurium and Escherichia coli.

Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage

InactiveUS6962930B1Lack of unwanted stimulatory effectReduce and prevent in vitro measureBiocideNervous disorderVoltage-sensitive sodium channelN-Methyl-D-aspartic acid
Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e.g. ethanol, barbiturates, opiates etc.). The combined actions of the disclosed compound on VSNaC and NMDA receptors also impart properties to these compounds that are important in preventing and reducing excitotoxic neurodegeneration and reducing anxiety without the undesirable CNS depressant side-effects of agents hitherto employed for these purposes.
Owner:LOHOCLA RES CORP

Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them

InactiveUS20120040993A1Good transport propertyBiocideAntimycoticsDrugNeuroprotective factors
Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and / or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and / or treated by iron chelation therapy, and / or neuroprotection and / or neurorestoration, and / or apoptosis inhibition and / or MAO inhibition and / or cholinesterase inhibition and / or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI.
Owner:YEDA RES & DEV CO LTD +1

Small interfering RNA for gene knockdown of the subcutaneous n-methyl-d-aspartate receptor nr1 subunit, and it's application on pharmaceutics

A small interfering RNA for gene knockdown of the N-methyl-D-aspartate receptor NR1 subunit comprises 21 to 25 ribonucleic acids, which are homologous to the RNA sequence of N-methyl-D-aspartate receptor NR1 subunit. A method of using the small interfering RNA, applying the small interfering RNA on subcutaneous tissues temporary interfere with the genetic expression of the NMDA receptor NR1 subunit in hypoderm. A use of the small interfering RNA on pharmaceutics, applying the small interfering RNA manufacture into new analgesic drugs for moderating the inflammatory pain or intolerable chronic pain, especially on clinical chronic pain and burn pain patients. An analgesic drug for skin inflammatory pain comprising: the small interfering RNA and a siRNA acceptable vehicle.
Owner:I-SHOU UNIVERSITY

Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

PendingCN114008204APrevent or significantly reduce the risk of clinical relapseNo or reduced immunosuppressionOrganic active ingredientsNervous disorderAutoimmune conditionNmdar encephalitis
The invention relates to a chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR comprises an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system. The invention relates to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid molecule comprising a sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. In one embodiment, the autoantigen encoded by the nucleic acid sequence comprises or consists of an N- methyl-D-aspartate receptor (NMDAR), or one or more NMDAR fragments. The invention further relates to the chimeric autoantibody receptor (CAAR) protein of the invention, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR) of the invention, a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and the use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.
Owner:德国神经退行性疾病中心 +1

Expression and applications of GluN1/GluN2A tetramer of human N-methyl-D-aspartate receptor

The invention relates to expression and applications of GluN1 / GluN2A tetramer of a human N-methyl-D-aspartate receptor. It is revealed that some loci at the transmembrane and extracellular domains ofsubunits GluN1 and GluN2A of the N-methyl-D-aspartate receptor are closely related to the stability of recombinant expression of the receptor and the antigen-antibody binding activity. On the basis ofperforming mutation, recombinant expression can be performed by only obtaining the transmembrane and extracellular domains of a mutant, so that an N-methyl-D-aspartate receptor mutant with stable expression and a polymer form of an ideal spatial structure can be obtained. Therefore, the problems of instability of the type of protein and poor antibody binding capacity can be solved.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI +1

Method for acquiring B cell antibody gene for resisting N-methyl-D-aspartic acid receptor encephalitis and immune repertoire research of B cell antibody gene

The invention belongs to the technical field of gene engineering, and particularly relates to a method for acquiring single cell of B cell surface receptor (BCR) or an antibody gene of an anti-N-methyl-D-aspartic acid receptor encephalitis patient, and further discloses immune repertoire research of B cells of the anti-N-methyl-D-aspartic acid receptor encephalitis patient. According to a method for amplifying a variable region and a constant region of the single B cell humanized antibody gene and a method based on a single B cell reverse transcription and BCR amplification, the characteristicof antigen-antibody specific binding is used for the first time, a positive B cell combined with a pathogenic antigen NR1 protein subunit for resisting N-methyl-D-aspartic acid receptor encephalitisis screened out in advance by using a flow cytometry, the interference of other non-positive BCR/antibody information is reduced, the unnecessary workload is reduced, the correlation between the finally obtained antibody information and the disease is stronger, the efficiency of capturing the single-cell B cell antibody sequence is higher, the experiment steps are simpler and more convenient, andthe operability is stronger.
Owner:INST OF PSYCHOLOGY CHINESE ACADEMY OF SCI

Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief

A multimodal anti-emetic anesthetic / analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free / sparing anesthetic / analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics / analgesics. The formulation is administered to a mammal in need of anesthesia / analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.
Owner:HUTCHISON HEALTH LLC

Ntranasal dantrolene administration for treatment of alzheimer's disease

PendingUS20220354827A1Reduce releaseImproving and slowing declineOrganic active ingredientsNervous disorderRyanodine receptorSynaptogenesis
Methods for inhibiting impaired neurogenesis and / or synaptogenesis in neurons in a subject with or suspected of having Alzheimer's Disease (AD), methods for improving and / or slowing the decline of cognitive function after onset of neuropathology and cognitive dysfunction, which neuropathology and cognitive dysfunction are caused by AD, methods for improving and / or slowing the decline of memory before onset of symptoms of AD, methods for increasing concentration and duration of dantrolene in the brain, and methods for improving and / or slowing the decline of memory after onset of symptoms of AD, the methods comprising intranasally administering to a subject in need thereof an amount of a pharmaceutical composition comprising dantrolene effective to inhibit over-activation of N-methyl-D-aspartate (NMVDA) receptor and / or ryanodine receptor (RyR). Methods further comprise administering a therapeutically effective amount of a glutamate receptor antagonist to the subject.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Anti-nmda receptor antibodies and methods of use

A recombinant, synthetic or monoclonal human antibody or fragment thereof that binds to an N-methyl-D-aspartate Receptor (NMDAR) epitope, which antibody or fragment comprises at least one a heavy chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs. 1, 3, or 5; or at least one a light chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs: 2, 4, or 6. Assays for diagnosis of ANRE employ these NMDAR-binding antibodies, constructs, or epitope binding fragments. In one embodiment, multiple of the NMDAR-binding antibodies or fragments are used as controls because they bind non-overlapping target sequences on the NMDAR ATD.
Owner:LANKENAU INST FOR MEDICAL RES

Methods and compositions for the treatment of opioid dependence and for the treatment of pain

The present invention relates to methods of treating opioid dependence, enhancing the treatment of opioid dependence, treating opioid withdrawal, or alleviating one or more opioid withdrawal symptoms in a subject, preventing or reducing the likelihood of opioid dependence relapse in a subject treated for opioid dependence, reducing the vulnerability of a subject to develop opioid dependence in adulthood following opioid exposure during adolescence, or treating pain in a subject, comprising administering a therapeutically effective amount of a N-methyl-D-aspartate receptor (NMDA) partial agonist to the subject. The present invention further relates to compositions comprising an NMDA partial agonist for use with the aforementioned methods.
Owner:DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products